Treatment perspectives for human African trypanosomiasis

Fundamental and Clinical Pharmacology

Volumn 17, Issue 2, 2003, Pages 171-181

  Bouteille, Bernard ^a   Oukem, Odile ^b   Bisser, Sylvie ^b   Dumas, Michel ^a  

^a UNIVERSITY OF LIMOGES   (France)

^b CENTRE INTERNATIONAL DE RECHERCHES MÉDICALES DE FRANCEVILLE   (Gabon)

Author keywords

Current management; Human African trypanosomiasis; Therapeutic perspectives

Indexed keywords

DIMINAZENE ACETURATE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PENTAMIDINE MESYLATE; SURAMIN;

ABDOMINAL PAIN; ABSCESS; AFRICAN TRYPANOSOMIASIS; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN DISEASE; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CHAGAS DISEASE; CONGO; DIABETES MELLITUS; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING LOSS; HEART ARRHYTHMIA; HEMOLYMPH; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INOCULATION; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NERVE INJURY; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RASH; SEIZURE; THROMBOCYTOPENIA; TRYPANOSOMA BRUCEI; VOMITING; WEIGHT REDUCTION;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE; TRYPANOSOMIASIS, AFRICAN;

EID: 0242500852     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00167.x     Document Type: Article

References (109)

1. Smith D.H., Pépin J., Stich A.H.R. Human African trypanosomiasis: an emerging public health crisis. Brit. Med. Bull. (1998) 54 341-355.
2. Moore A., Richer M. Re-emergence of epidemic sleeping sickness in southern Sudan. Trop. Med. Int. Health (2001) 6 342-347.
3. Stanghellini A., Josenando T. The situation of sleeping sickness in Angola: a calamity. Trop. Med. Int. Health (2001) 6 330-334.
4. Van Nieuwenhove S., Betu-Ku-Mesu V.K., Diabakana P.M., Declercq J., Miaka C. Sleeping sickness resurgence in the DRC: the past decade. Trop. Med. Int. Health (2001) 6 335-341.
5. Dumas M., Bouteille B., Buguet A. Progress in human African trypanosomiasis, sleeping sickness, Springer-Verlag, Paris, France, 1999.
6. Wéry M. Trypanosomoses africaines, maladie du sommeil. Encyclopédie Médico-Chirurgicale, Maladies infectieuses. 8-540-A-20, Ed. Scientifiques et Médicales Elsevier SAS, Paris, France, 2000, 20 pp.
7. Boa F.Y., Traore M.A., Doua F., Kouassi-Traore M.T., Giordano C. Les différents aspects cliniques actuels de la THA à T. b. g Analyse de 300 dossiers du foyer de Daloa, Côte d'Ivoire. Bull. Soc. Path. Ex. (1988) 81 427-444.
8. Dumas M., Bisser S. Clinical aspects of human African trypanosomiasis (Chapter 13). in: Dumas M., Bouteille B., Buguet A.(Eds.), Progress in human African trypanosomiasis, sleeping sickness. Springer-Verlag, Paris, France, 1999, pp. 215-233.
9. Bisser S., Bouteille B., Sarda J. et al. Apport des examens biochimiques dans le diagnostic de la phase nerveuse de la trypanosomose humaine africaine. Bull. Soc. Path. Ex. (1997) 90 321-326.
10. Bisser S., Lejon V., Preux P.M. et al. Blood-cerebrospinal fluid barrier and intrathecal immunoglobulins compared to field diagnosis of central nervous system involvement in sleeping sickness. J. Neurol. Sci. (2002) 193 127-135.
11. Buguet A., Bourdon L., Bouteille B. et al. The duality of sleeping sickness: focusing on sleep. Sleep Med. Rev. (2001) 5 139-153.
12. WHO. Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee. Technical Report Series no. 881, Geneva, Switzerland, 1995.
13. Atouguia J., Costa J. Therapy of human African trypanosomiasis: current situation. Mem. Inst. Osw. Cruz (1999) 94 221-224.
14. Van Nieuwenhove S. Present strategies in the treatment of human African trypanosomiasis (Chapter 15), in: Dumas M., Bouteille B., Buguet A. (Eds.), Progress in human African trypanosomiasis, sleeping sickness, Springer-Verlag, Paris, France, 1999, pp. 253-280.
15. WHO. L'Organisation Mondiale de la Santé et Aventis annoncent une initiative majeure pour intensifier la lutte contre la maladie du sommeil. Communiqué OMS/23, 3 mai 2001 (web site; http://who.int/inf-pr-2001/fr/cp2001-23.html).
16. Wang C.C. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu. Rev. Pharmacol. Toxicol. (1995) 35 93-127.
17. Bitonti A.J., Dumont J.A., Mc Cann P.P. Characterization of Trypanosoma brucei brucei S-adenosyl-L-methionine decarboxylase and its inhibition by Berenil, pentamidine and methylglyoxal bis(guanylhydrazone). Biochem. J. (1986) 237 518-521.
18. Berger B.J., Carter N.S., Fairlamb A.H. Polyamine and pentamidine metabolism in African trypanosomes. Acta Trop. (1993) 54 215-224.
19. de Koning H.P. Transporters in African trypanosomes: role in drug action and resistance. Int. J. Parasitol. (2001) 31 512-522.
20. Bronner U, Doua F, Ericsson O. et al. Pentamidine concentrations in plasma, whole blood and cerebrospinal fluid during treatment of Trypanosoma gambiense infection in Cote d'Ivoire. Trans. R. Soc. Trop. Med. Hyg. (1991) 85 608-611.
21. Bronner U., Gustafsson L.L., Doua F. et al. Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness. Br. J. Clin. Pharmacol. (1995) 39 289-295.
22. Rombo L. Pentamidine concentrations in plasma, whole blood and cerebro-spinal fluid during treatment of Trypanosoma gambiense infection in Côte d'Ivoire. Trans. R. Soc. Trop. Med. Hyg. (1991) 85 608-611.
23. Miézan T.W., Bronner U., Doua F., Cattand P., Rombo L. Long term exposure of Trypanosoma brucei gambiense to pentamidine in vitro. Trans. R. Soc. Trop. Med. Hyg. (1994) 88 332-333.
24. Apted F.I.C. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Eastern Hemisphere. Pharmac. Ther. (1980) 11 391-413.
25. Doua F., Miézan T.W., Sanon Singaro J.R., Boa Yapo F., Baltz T. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am. J. Trop. Med. Hyg. (1996) 55 586-588.
26. Coulaud J., Caquet R., Froli G., Saimot G., Pasticier A., Payet M. Atteintes rénale et pancréatique sévères an cours d'un traitement par la pentamidine d'une trypanosomiase africaine. Ann. Med. Interne (1975) 10 665-669.
27. Voogd T.E., Vansterkenburg E.L.M., Wilting J., Janssen L.H.M. Recent research on the biological activity of Suramin. Pharmacol. Rev. (1993) 45 177-203.
28. Willson M., Callens M., Kuntz D.A., Perié J., Opperdoes F.R. Synthesis and activity of inhibitors highly specific for the glycolytic enzymes from Trypanosoma brucei. Mol. Biochem. Parasitol. (1993) 59 201-210.
29. Opperdoes F.R., Borst P. Localization of nine glycolytic enzymes in a microbody-like organelle in Trypanosoma brucei: the glycosome. FEBS Lett. (1977) 80 360-364.
30. Opperdoes F.R., Baudhuin P., Coppens I., DeRoe C., Edwards S.W. Purification, morphometric analysis and characterization of the glycosomes (microbodies) of the protozoan haemoflagellate. J. Cell Biol. (1984) 98 1178-1184.
31. Périé J., Rivière-Alric I., Blonski C. et al. Inhibition of the glycolytic enzymes in the trypanosome: an approach in the development of new leads in the therapy of parasitic diseases. Pharmac. Ther. (1993) 60 347-365.
32. Fairlamb A.H., Bowman I.B.R. Uptake of the trypanocidal drug suramin by bloodstream forms of Trypanosoma brucei and its effect on respiration and growth rate in vivo. Mol. Biochem. Parasitol. (1980) 1 315-333.
33. Collins J.M., Klecker R.W., Yarchoan R. et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol. (1986) 26 22-26.
34. Wellde B.T., Chumo D.A., Reardon M.J. et al. Treatment of Rhodesian sleeping sickness in Kenya. Ann. Trop. Med. Parasitol. (1989) 66 7-14.
35. Arroz J., Djedje M. Suramin and metronidazole in the treatment of Trypanosoma brucei rhodesiense. Trans. R. Soc. Trop. Med. Hyg. (1988) 82 421.
36. Taelman H., Clerinx J., Bogaerts J., Vervoort T. Combination treatment with suramin and eflornithine in late stage Rhodesian trypanosomiasis: case report. Trans. R. Soc. Trop. Med. Hyg. (1996) 90 572-573.
37. Veeken H.J.G.M., Ebeling M.C.H., Dolmans W.M.V. Trypanosomiasis in a rural hospital in Tanzania. A retrospective study of its management and the result of treatment. Trop. Geogr. Med. (1988) 41 113-117.
38. Pépin J., Milord F., Guern C., Mpia B., Ethier L., Mansinda D. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Lancet (1989) 333 1246-1250.
39. Burri C., Blum J. A case of reactive encephalopathy after treatment with suramin of stage I sleeping sickness. Trop. Med. Int. Health (1996) 1 A36.
40. Friedheim E.A.H. Mel B in the treatment of human trypanosomiasis. Am. J. Trop. Med. Hyg. (1949) 29 173-180.
41. Fairlamb A.H., Henderson G.H., Cerami A. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc. Natl. Acad. Sci. USA (1989) 86 2607-2611.
42. Burri C., Brun R. An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid. Trop. Med. Parasitol. (1992) 43 223-225.
43. Burri C., Baltz T., Giroud C., Doua F., Welker H.A., Brun R. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy (1993) 39 225-234.
44. Bronner U., Brun R., Burri F. et al. Determination of melarsoprol concentrations in plasma, urine and CSF in patients with human African trypanosomiasis using HPLC and bioassay. Trop. Med. Int. Health (1996) 1 A37.
45. Neujean G. Contribution à l'étude des liquides rachidiens et céphaliques dans la maladie du sommeil à Trypanosoma gambiense. Ann. Soc. Belge Med. Trop. (1950) 30 1125-1387.
46. Burri C., Nkunku S., Merolle A., Smith T., Blum J., Brun R. Efficacy of a new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet (2000) 355 1419-1425.
47. Arroz J.O.L. Melarsoprol and reactive encephalopathy in Trypanosoma brucei rhodesiense. Trans. R. Soc. Trop. Med. Hyg. (1987) 81 192.
48. Pépin J., Milord F. The treatment of human African trypanosomiasis. Adv. Parasitol. (1994) 33 2-49.
49. Legros D., Evans S., Maiso F., Enyaru J.C.K., Mbulamberi D. Risk factors for treatment failure after melarsoprol for T. b. gambiense trypanosomiasis in Uganda. Trans. R. Soc. Trop. Med. Hyg. (1999) 93 439-442.
50. Doua F., BoaYapo F. Human trypanosomiasis in the Ivory coast: therapy and problems. Acta Trop. (1993) 54 163-168.
51. Ancelle T., Barret B., Flachet L., Moren A. Etude de 2 épidémies d'encéphalopathies arsénicales dans le traitement de la trypanosomiase, Ouganda, 1992-1993. Bull. Soc. Path. Ex. (1994) 87 341-346.
52. Pépin J., Milord F., Khonde A., Niyonsenga T., Loko L., Mpia B. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. (1995) 89 92-97.
53. Nkanga N.G., Mutombo L., Kazidi K., Kazyumba G.L. Neuropathies arsenicales après traitement de la trypanosomiase humaine au mélarsoprol. Med. Afr. Noire (1988) 35 73-76.
54. Blum J., Nkunku S., Burri C. Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis. Trop. Med. Int. Health (2001) 6 390-400.
55. Dutertre J., Labusquière R. La thérapeutique de la trypanosomiase. Med. Trop. (1966) 26 342-356.
56. Bertrand E., Rive J., Serié F., Kone I. Encéphalopathie arsenicale et traitement de la trypanosomiase. Méd. Trop. (1973) 33 385-390.
57. Buyst H. The treatment of T. rhodesiense sleeping sickness with special reference to its physio-pathological and epidemiological basis. Ann. Soc. Belge Med. Trop. (1975) 55 95-104.
58. Apted F.I.C. Four years' experience of Mdarsen Oxide/BAL in the treatment of late-stage Rhodesian sleeping sickness. Trans. R. Soc. Trop. Med. Hyg. (1957) 5 75-86.
59. Sina G.C., Triolo N., Trova P., Clabaut J.M. L'encéphalopathie arsénicale lors du traitement de la trypanosomiase humaine africaine à T. gambiense (à propos de 16 cas). Ann. Soc. Belge Med. Trop. (1977) 57 67-74.
60. Miranda-Nieves G., Janssen P. Encéphalopathie oedémateuse brutale dans une trypanosomiase guérie. Acta Neurol. Psychiatr. Belgica (1965) 65 368-390.
61. Sina G.C., Triolo N., Cramet B., SuhBandu M. L'adrénaline dans la prévention et le traitement des accidents de l'arsobalthérapie. A propos de 776 cas de trypanosomiase humaine africaine à T. gambiense traités dans les formations sanitaires de Fontem (R.U. du Cameroun). Med. Trop. (1982) 42 531-536.
62. Apted F.I.C. Treatment of human trypanosomiasis, in: Mulligan H.W.(ed.). The African trypanosomiases. George Allen and Unwin, London, 1970, p. 684.
63. Bacchi C.J., Nathan H.C., Hutner S.H., Mc Cann P.P., Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science (1980) 210 332-334.
64. VanNieuwenhove S., Declercq J. Difluoromethylornithine: a new promising drug against gambiense sleeping sickness. Case Report, in: Proceedings 17th meeting ISCTRC, Arusha, OAU/STRC, Nairobi, Kenya, 1981, p. 213.
65. Giffin B.F., Mc Cann P.P., Bitonti A.J., Bacchi C.J. Polyamine depletion following exposure to DL-alpha-difluoromethylornithine both in vivo and in vitro initiates morphological alterations and mitochondrial activation in a monomorphic strain of Trypanosoma brucei brucei. J. Protozool. (1986) 33 238-243.
66. Bitonti A.J., Mc Cann P.P., Sjoerdsma A. Necessity of antibody response in the treatment of African trypanosomiasis with alpha-difluoromethylornithine. Biochem. Pharmacol. (1986) 35 331-334.
67. Haegele K.D. Kinetics of alpha-difluoromethylornithine: an irreversible inhibitor of ornithine decarboxylase. Clin. Pharmac. Ther. (1981) 30 210-217.
68. Iten M., Matovu E., Brun R., Kaminsky R. Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-α-difluoromethylornithine (DFMO). Trop. Med. Parasitol. (1995) 46 190-195.
69. Van Nieuwenhove S., Schechter P.J., Declercq J., Boné G., Burke J., Sjoerdsma A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase: first field trial. Trans. R. Soc. Trop. Med. Hyg. (1985) 79 692-698.
70. Milord F., Pépin J., Loko L., Ethier L., Mpia B. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet (1992) 340 652-655.
71. Pépin J., Ethier L., Kazadi C., Milord F., Ryder R. The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Am. J. Trop. Med. Hyg. (1992) 47 133-140.
72. Pépin J., Khonde N., Maiso F. et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull. World Health Organ. (2000) 78 1283.
73. WHO/TDR. TDR Progress 1999-2000: new and improved tools (web site: http://www.who.int/tdr/research/progress9900/drugs-tryps.htm).
74. Doua F., Boa F.Y., Schechter P.J. et al. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine). Efficacy and tolerance in 14 cases in Côte d'Ivoire. Am. J. Trop. Med. Hyg. (1987) 37 525-533.
75. Townson S.M., Boreham P.L.F., Upcroft P., Upcroft J.A. Resistance to nitroheterocyclic drugs. Acta Trop. (1994) 56 125-141.
76. Fairlamb A.H., Henderson G.H., Cerami A. Trypanothione: a novel bis(gluthathionyl)spermidine cofactor for gluthathione reductase in trypanosomatids. Science (1985) 227 1485-1487.
77. Fairlamb A.H. Future prospects for the chemotherapy of human trypanosomiasis 1. Novel approaches to the chemotherapy of trypanosomiasis. Trans. R. Soc. Trop. Med. Hyg. (1990) 84 613-617.
78. Fairlamb A.H. Trypanothione metabolism and rational approaches to drug design. Biochem. Soc. Trans. (1990) 18 717-720.
79. Docampo R., Moreno S.N.J. Free radical metabolism of antiparasitic agents. Proc. Fed. Am. Soc. Exp. Biol. (1986) 45 2471-2476.
80. 35S in the rat and dog. Arzneim. Forsch. (Drug Res.) (1972) 22 1617-1624.
81. Van Nieuwenhove S., Declercq J. Nifurtimox (Lampit) treatment in late stage of gambiense sleeping sickness, in: Proceedings 17th meeting ISCTRC, Arusha, OAU/STRC, Nairobi, Kenya, 1981, p. 206.
82. Van Nieuwenhove S., Declercq J. Nifurtimox therapy in late-stage arsenical refractory gambiense sleeping sickness, in: Proceedings 20th meeting ISCTRC, Mombasa, OAU/STRC, Nairobi, Kenya, 1989, p. 264.
83. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann. Soc. Belge Med. Trop. (1992) 72 39-51.
84. Moens F., De Wilde M., Ngato K. traitement au nifurtimox de la trypanosomiase humaine africaine. Ann. Soc. Belge Med. Trop. (1984) 64 37-43.
85. Pépin J., Milord F., Mpia B. et al. An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire. Trans. R. Soc. Trop. Med. Hyg. (1989) 83 514-517.
86. Pépin J., Milord F., Meurice F., Ethier L., Loko L., Mpia B. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in Zaire. Trans. R. Soc. Trop. Med. Hyg. (1992) 86 254-256.
87. Croft S. Pharmacological approaches to antitrypanosomal chemotherapy. Mem. Inst. Osw. Cruz (1999) 94 215-220.
88. Keiser J., Stich A., Burri C. New drugs for the treatment of human African trypanosomiasis. Trends Parasitol. (2001) 17 42-49.
89. Clarkson A.B., Bienen E.J., Bacchi C.J. et al. New drug combination for experimental late-stage African trypanosomiasis: DL-alpha-difluoromethylornithine (DFMO) with suramin. Am. J. Trop. Med. Hyg. (1984) 33 1073-1077.
90. Sayer P.D., Gould S.S., Waitumbi J.N., Murray P.K., Njogu A.R. The successful treatment of Trypanosoma rhodesiense infected monkeys with low doses of melarsoprol or with suramin and nitroimidazole, in: Proceedings 18th meeting ISCTRC, Harare, OAU/STRC, Nairobi, Kenya, 1985, p. 131.
91. Raseroka B.H., Ormerod W.E. Suramin/metronidazole combination for African sleeping sickness. Lancet (1985) ii 784-785.
92. Raseroka B.H., Ormerod W.E. The trypanocidal effect of drugs in different parts of the brain. Trans. R. Soc. Trop. Med. Hyg. (1986) 80 634-641.
93. Bacchi C.J., Nathan H.C., Clarkson A.B. et al. Effect of ornithine decarboxylase inhibitors DL-alpha-difluoromethylornithine and alpha-monofluoromethyldehydroornithine methyl ester alone and in combination with suramin against Trypanosoma brucei brucei central nervous system models. Am. J. Trop. Med. Hyg. (1987) 36 46-52.
94. Bouteille B, Dardé ML, Pestre-Alexandre M. Efficacité du nifurtimox sur Trypanosoma brucei brucei in vitro et in vivo sur souris Swiss. Etude préliminaire. Bull. Soc. Fr. Parasitol. (1988) 6 15-20.
95. Jennings F.W. Combination chemotherapy of CNS trypanosomiasis. Acta Trop. (1993) 54 205-213.
96. Foulkes J.R. Metronidazole and suramin combination in the treatment of arsenical refractory Rhodesian sleeping sickness - a case study. Trans. R. Soc. Trop. Med. Hyg. (1996) 90 422.
97. Janssens P.G., De Muynck A. Clinical trials with 'Nifurtimox' in African trypanosomiasis. Ann. Soc. Belge Med. Trop. (1977) 57 475-479.
98. Simarro P.P., Ndong Asumo P. Gambian trypanosomiasis and synergism between melarsoprol and eflornithine. Trans. R. Soc. Trop. Med. Hyg. (1996) 90 315.
99. Bacchi C.J., Vargas M., Rattendi D., Goldberg B., Zhou W. Antitrypanosomal activity of a new triazine derivative, SIPI 1029. in vitro and in model infections. Antimicrob. Agents Chemother. (1998) 42 2718-2721.
100. Brun R., Burri C., Gichuki C.W. The story of CGP 40215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense. Trop. Med. Int. Health (2001) 6 362-368.
101. Bacchi C.J., Brun R., Croft S.L., Alicea K., Buhler Y. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob. Agents Chemother. (1996) 40 1448-1453.
102. Hall J.E., Kerrigan J.E., Ramachandran K. et al. Anti-Pneumocystis activities of aromatic diamidoxime prodrugs. Antimicrob. Agents Chemother. (1998) 42 666-674.
103. Seed J.R., Tidwell R.R., Boykin D.W., Hall J.E. New pentamidine analogues for the treatment of African trypanosomiasis. 53rd Annual Meeting of the Society of Protozoologists. June 25-28. J. Euk. Microbiol. (web site: http://www.jeukmic.org/abstr/int/93/a333.html).
104. Donkor I.O., Assefa H., Rattendi D. et al. Trypanocidal activity of dicationic compounds related to pentamidine. Eur. J. Med. Chem. (2001) 36 531-538.
105. Bouteille B, Chauvière G. Implication du mégazol dans la chimiothérapie des trypanosomoses. Med. Trop. (1999) 59 321-330.
106. Bouteille B., Marie-Daragon A., Chauvière G. et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop. (1995) 60 73-80.
107. Enanga B., Keita M., Chauvière G., Dumas M., Bouteille B. Megazol combined with suramin: a chemotherapy regimen which reversed the CNS pathology in a model of human African trypanosomiasis in mice. Trop. Med. Int. Health (1998) 3 36-41.
108. Enanga B., Mezui Me Ndong, Boudra H. et al. Pharmacokinetics, metabolism and excretion of megazol in a Trypanosoma brucei gambiense primate model of human African trypanosomiasis: preliminary study. Arzneimittelforschung Drug Res.(2000) 50 158-162.
109. Legros D., Ollivier G., Gastellu-Etchegorry M. et al. Treatment of human African trypanosomiasis - present situation and needs for research and development. Lancet Infect. Dis. (2002) 2 437-440.